## Proceedings of the 27th Princeton Conference: Preface

Karen L. Furie, MD, MPH

---

## Risk and Prevention

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stroke Risk and Prevention: Introduction</td>
<td>Philip B. Gorelick, MD, MPH, FACP; Ralph L. Sacco, MD, MS, FAHA</td>
<td>S2</td>
</tr>
<tr>
<td>Inflammatory Mechanisms of Stroke</td>
<td>Mitchell S.V. Elkind, MD, MS</td>
<td>S3</td>
</tr>
<tr>
<td>Emerging Risk Factors in Women</td>
<td>Kathryn M. Rexrode, MD, MPH</td>
<td>S9</td>
</tr>
<tr>
<td>Advanced Contrast-Enhanced MRI for Looking Beyond the Lumen to Predict Stroke: Building a Risk Profile for Carotid Plaque</td>
<td>Bruce A. Wasserman, MD</td>
<td>S12</td>
</tr>
<tr>
<td>The Evolving Field of Stroke Prevention in Patients With Atrial Fibrillation</td>
<td>Michael D. Ezekowitz, MBChB, DPhil; Timothy H. Aikens, BA; Annamarie Brown; Zack Ellis</td>
<td>S17</td>
</tr>
</tbody>
</table>

## Interventional Approaches

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoluminal Scaffolds for Vascular Reconstruction and Exclusion of Aneurysms From the Cerebral Circulation</td>
<td>Baruch B. Lieber, PhD; Chander Sadasivan, PhD</td>
<td>S21</td>
</tr>
<tr>
<td>Is Patent Foramen Oval a Modifiable Risk Factor for Stroke Recurrence?</td>
<td>David M. Kent, MD, MS; David E. Thaler, MD, PhD</td>
<td>S26</td>
</tr>
<tr>
<td>The Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST): Stenting Versus Carotid Endarterectomy for Carotid Disease</td>
<td>Vito A. Mantese, MD; Carlos H. Timaran, MD; David Chiu, MD; Richard J. Begg, MD; Thomas G. Brott, MD; for the CREST Investigators</td>
<td>S31</td>
</tr>
</tbody>
</table>

## Future of Prevention

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>What Is the Future of Stroke Prevention? Debate: Polypill Versus Personalized Risk Factor Modification</td>
<td>Walter N. Kernan, MD; Lenore J. Launer, PhD; Larry B. Goldstein, MD, FAAN</td>
<td>S35</td>
</tr>
</tbody>
</table>

## Approaches to Thrombolysis

<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasminogen Activators in Ischemic Stroke: Introduction</td>
<td>Gregory J. del Zoppo, MD</td>
<td>S39</td>
</tr>
</tbody>
</table>
Intracerebral Hemorrhage: Introduction
Gregory M. Lanza, MD, PhD; Jon N. Marsh, PhD; Grace Hu, MS; Michael J. Scott, BS; Anne H. Schmieder, MS; Shelton D. Caruthers, PhD; Dipanjan Pan, PhD; Samuel A. Wickline, MD .......................... S42

Thrombolysis With Plasmin: Implications for Stroke Treatment
Victor J. Marder, MD; Reza Jahan, MD; Theresa Gruber, MS; Abha Goyal, MD; Vik Arora, PhD .......................... S45

Ultrasound-Assisted Thrombolysis for Stroke Therapy: Better Thrombus Break-Up With Bubbles
Kathryn E. Hitchcock, PhD; Christy K. Holland, PhD .......................... S50

Annexin A2: A Tissue Plasminogen Activator Amplifier for Thrombolytic Stroke Therapy
Xiang Fan, MD; Zhanyang Yu, Ph.D; Jianxiang Liu, Ph.D; Ning Liu, BS; Katherine A. Hajjar, MD; Karen L. Furie, MD; Eng H. Lo, PhD; Xiaooying Wang, MD, PhD .......................... S54

The Economic Case for New Stroke Thrombolytics
S. Claiborne Johnston, MD, PhD .......................... S59

Neuroprotection
Neuroprotection: Introduction
Richard J. Traystman, PhD .......................... S63

Neonatal Stroke in Mice Causes Long-Term Changes in Neuronal Notch-2 Expression That May Contribute to Prolonged Injury
Lavinia Albéri, PhD; Zhikai Chi, PhD; Shilpa D. Kadam, PhD; Justin D. Mulholland, BS; Valina L. Dawson, PhD; Nicholas Gaiano, PhD; Anne M. Comi, MD .......................... S64

Therapeutic Hypothermia for Brain Ischemia: Where Have We Come and Where Do We Go?
Midori A. Yenari, MD; Thomas M. Hemmen, MD, PhD .......................... S72

Modulation of the Postischemic Immune Response to Improve Stroke Outcome
Kyro J. Becker, MD .......................... S75

Neuroprotection in Subarachnoid Hemorrhage
Daniel T. Laskowitz, MD, MHS; Brad J. Kolls, MD, PhD .......................... S79

Neuroprotection Controversy
Brain Protection: Maybe Yes, Maybe No
Michael A. Moskowitz, MD .......................... S85

Can Molecular and Cellular Neuroprotection Be Translated Into Therapies for Patients? Yes, but Not the Way We Tried It Before
Michael Tymianski, MD, PhD, FRCSC .......................... S87

Intracerebral Hemorrhage
Intracerebral Hemorrhage: Introduction
Steven M. Greenberg, MD, PhD; James C. Grotta, MD; Guohua Xi, MD .......................... S91

Evaluating Strategies for the Treatment of Cerebral Cavernous Malformations
Dean Y. Li, MD, PhD; Kevin J. Whitehead, MD .......................... S92

Rodent Models of Intracerebral Hemorrhage
Crystal L. MacLellan, PhD; Gergely Silasi, MSc; Angela M. Auriat, BSc; Frederick Colbourne, PhD .......................... S95

Neuroprotective Strategies for Intracerebral Hemorrhage: Trials and Translation
Christopher P. Kellner, MD; E. Sander Connolly, Jr, MD .......................... S99

Prevalence and Risk Factors of Cerebral Microbleeds: An Update of the Rotterdam Scan Study
Mariëlle M.F. Poels, MD; Meike W. Vernooij, MD, PhD; M. Arfan Ikram, MD, PhD; Albert Hofman, MD, PhD; Gabriel P. Krestin, MD, PhD; Aad van der Lugt, MD, PhD; Monique M.B. Breteler, MD, PhD .......................... S103

Intracerebral Hemorrhage and Head Trauma: Common Effects and Common Mechanisms of Injury
William J. Powers, MD .......................... S107
Recovery

Recovery: Introduction
Randolph J. Nudo, PhD, Argye E. Hillis, MD, MA .................................................. S111

MRI Evaluation of White Matter Recovery After Brain Injury
Quan Jiang, PhD; Zheng Gang Zhang, MD, PhD; Michael Chopp, PhD .................................. S112

Stratifying Patients With Stroke in Trials That Target Brain Repair
Steven C. Cramer, MD ................................................................. S114

In Vivo 2-Photon Imaging of Fine Structure in the Rodent Brain: Before, During, and After Stroke
Albrecht Sigler, PhD; Timothy H. Murphy, PhD .................................................. S117

Targets for Neural Repair Therapies After Stroke
S. Thomas Carmichael, MD, PhD .................................................. S124

Vascular Cognitive Impairment

Vascular Cognitive Impairment: Introduction
Costantino Iadecola, MD; Vladimir Hachinski, MD; Gary A. Rosenberg, MD .................................. S127

CADASIL: Experimental Insights From Animal Models
Cenk Ayata, MD ................................................................. S129

Enhanced Capillary Amyloid Angiopathy-Associated Pathology in Tg-SwDI Mice With Deleted Nitric Oxide Synthase 2
William E. Van Nostrand, PhD; Feng Xu, MD; Annemieke J.M. Rozemuller, MD, PhD; Carol A. Colton, PhD .......... S135

Leukoaraiosis and Stroke
Eric E. Smith, MD, MPH ................................................................. S139

Where Vascular Meets Neurodegenerative Disease
Julie A. Schneider, MD, MS; David A. Bennett, MD .................................................. S144

Imaging

Early Experience of Translating pH-Weighted MRI to Image Human Subjects at 3 Tesla
Phillip Zhe Sun, PhD; Thomas Benner, PhD; William A. Copen, MD; A. Gregory Sorensen, MD .......... S147

The Future of Stroke Imaging: What We Need and How to Get to It
Carlos Leiva-Salinas, MD; Max Wintermark, MD .................................................. S152

Imaging Small Vessel Disease: Lesion Topography, Networks, and Cognitive Deficits Investigated With MRI
Michael O’Sullivan, MRCP, PhD .................................................. S154

On the cover: The illustration is taken from an article in this issue, “Early Experience of Translating pH-Weighted MRI to Image Human Subjects at 3 Tesla” by Sun et al (Stroke. 2010;41[suppl 1]:S147–S151).